{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T22:35:40Z","timestamp":1789079740041,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.4158\/ep-2018-0022","type":"journal-article","created":{"date-parts":[[2018,8,7]],"date-time":"2018-08-07T11:22:29Z","timestamp":1533640949000},"page":"710-717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Prognostic Utility of 24-Hour Urinary 5-Hiaa Doubling Time in Patients With Neuroendocrine Tumors"],"prefix":"10.1016","volume":"24","author":[{"given":"Amit","family":"Tirosh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naris","family":"Nilubol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhaval","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Electron","family":"Kebebew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4158\/EP-2018-0022_bb0010","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/MPA.0b013e3181ec124e","article-title":"The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems","volume":"39","author":"Klimstra","year":"2010","journal-title":"Pancreas"},{"key":"10.4158\/EP-2018-0022_bb0015","unstructured":"American Joint Committee on CancerAJCC cancer staging manual. Available at: http:\/\/www.springer.com\/us\/book\/9783319406176. Accessed November 6, 2017."},{"key":"10.4158\/EP-2018-0022_bb0020","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000457956","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pathology: diagnosis and prognostic stratification","volume":"105","author":"Perren","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.4158\/EP-2018-0022_bb0025","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000443171","article-title":"ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors","volume":"103","author":"Falconi","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.4158\/EP-2018-0022_bb0030","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000443170","article-title":"ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum","volume":"103","author":"Niederle","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.4158\/EP-2018-0022_bb0035","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000472254","article-title":"ENETS consensus guidelines for standard of care in neuroendocrine tumours: biochemical markers","volume":"105","author":"Oberg","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.4158\/EP-2018-0022_bb0040","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1177\/0004563215613109","article-title":"Serum and plasma 5-hydroxyindoleacetic acid as an alternative to 24-h urine 5-hydroxyindoleacetic acid measurement","volume":"53","author":"Adaway","year":"2016","journal-title":"Ann Clin Biochem"},{"key":"10.4158\/EP-2018-0022_bb0045","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/00000658-198404000-00014","article-title":"Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma","volume":"199","author":"Miyauchi","year":"1984","journal-title":"Ann Surg"},{"key":"10.4158\/EP-2018-0022_bb0050","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1210\/jc.2005-0044","article-title":"Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma","volume":"90","author":"GTE Study Group","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP-2018-0022_bb0055","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.1158\/1078-0432.CCR-03-0788","article-title":"Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer","volume":"10","author":"Kelloff","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.4158\/EP-2018-0022_bb0060","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1089\/thy.2016.0031","article-title":"Serum thyroglobulin doubling time in progressive thyroid cancer","volume":"26","author":"R\u00f6ssing","year":"2016","journal-title":"Thyroid"},{"key":"10.4158\/EP-2018-0022_bb0065","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/jso.21451","article-title":"Preoperative tumor marker doubling time is a useful predictor of recurrence and prognosis after hepatic resection of hepatocellular carcinoma","volume":"102","author":"Masuda","year":"2010","journal-title":"J Surg Oncol"},{"key":"10.4158\/EP-2018-0022_bb0070","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1159\/000458155","article-title":"ENETS consensus recommendations for the standards of care in neuroendocrine neoplasms: follow-up and documentation","volume":"105","author":"Knigge","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.4158\/EP-2018-0022_bb0075","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1530\/EJE-16-1079","article-title":"Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total 68Ga-DOTATATE-avid tumor volume measurements","volume":"176","author":"Tirosh","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"10.4158\/EP-2018-0022_bb0080","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1200\/JCO.2015.64.0987","article-title":"Prospective study of 68Ga-DOTATATE positron emission tomography\/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites","volume":"34","author":"Sadowski","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.4158\/EP-2018-0022_bb0085","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1093\/clinchem\/48.11.2049","article-title":"Liquid chromatographic\u2013tandem mass spectrometric method for the determination of 5-hydroxyindole-3-acetic acid in urine","volume":"48","author":"Kroll","year":"2002","journal-title":"Clin Chem"},{"key":"10.4158\/EP-2018-0022_bb0090","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/1097-0142(196111\/12)14:6<1272::AID-CNCR2820140618>3.0.CO;2-H","article-title":"A biomathematical approach to clinical tumor growth","volume":"14","author":"Schwartz","year":"1961","journal-title":"Cancer"},{"key":"10.4158\/EP-2018-0022_bb0095","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00535-011-0462-2","article-title":"Evaluation of molecular targeted cancer drug by changes in tumor marker doubling times","volume":"47","author":"Enooku","year":"2012","journal-title":"J Gastroenterol"},{"key":"10.4158\/EP-2018-0022_bb0100","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1530\/EJE-16-0392","article-title":"Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumors","volume":"175","author":"Zandee","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.4158\/EP-2018-0022_bb0105","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1097\/JTO.0000000000000022","article-title":"Epidermal growth factor receptor mutations: effect on volume doubling time of non\u2013small-cell lung cancer patients","volume":"9","author":"Nakamura","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.4158\/EP-2018-0022_bb0110","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.4158\/EP-2018-0022_bb0115","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1016\/S1470-2045(17)30335-2","article-title":"Incidence and prognosis of carcinoid syndrome: hormones or tumour burden?","volume":"18","author":"Zandee","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.4158\/EP-2018-0022_bb0120","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1016\/j.ejca.2007.07.025","article-title":"Persistent low urinary excretion of 5-HIAA is a marker for favourable survival during follow-up in patients with disseminated midgut carcinoid tumours","volume":"43","author":"van der Horst-Schrivers","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.4158\/EP-2018-0022_bb0125","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000225948","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine tumors: biochemical markers","volume":"90","author":"O'Toole","year":"2009","journal-title":"Neuroendocrinology"},{"key":"10.4158\/EP-2018-0022_bb0130","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1093\/clinchem\/46.10.1588","article-title":"Discriminating capacity of indole markers in the diagnosis of carcinoid tumors","volume":"46","author":"Meijer","year":"2000","journal-title":"Clin Chem"},{"key":"10.4158\/EP-2018-0022_bb0135","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/cncr.21291","article-title":"Carcinoids of the pancreas: an analysis of 156 cases","volume":"104","author":"Soga","year":"2005","journal-title":"Cancer"},{"key":"10.4158\/EP-2018-0022_bb0140","doi-asserted-by":"crossref","first-page":"e6201","DOI":"10.1097\/MD.0000000000006201","article-title":"Pancreatic carcinoids (serotonin-producing pancreatic neuroendocrine neoplasms)","volume":"96","author":"Tsoukalas","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.4158\/EP-2018-0022_bb0145","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/sj.bjc.6603699","article-title":"The prognostic role of WHO classification, urinary 5\u2013hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract","volume":"96","author":"Formica","year":"2007","journal-title":"Br J Cancer"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2035415X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2035415X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:04:58Z","timestamp":1761516298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X2035415X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S1530891X2035415X"],"URL":"https:\/\/doi.org\/10.4158\/ep-2018-0022","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Utility of 24-Hour Urinary 5-Hiaa Doubling Time in Patients With Neuroendocrine Tumors","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP-2018-0022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}